Bioprogress Share Discussion Threads

[anotherguru] 23/6/2008 11:27

mention bottoms and see who turns up!

[mad foetus] 23/6/2008 11:05

This fred aint wot it used to be back in the bprg days

[azuli] 23/6/2008 11:01

IT'S MY CORE COMPETENCY!!!!!

[anotherguru] 23/6/2008 11:00

AZ, ARE YOU GOOD AT PICKING BOTTOMS????

[waywardlad] 23/6/2008 10:59

I'LL BELIEVE IT WHEN I SEE IT!!

[azuli] 23/6/2008 10:58

I THINK WE'VE BOTTOMED OUT NOW!!!!!!

[debaleb] 23/6/2008 10:56

R WE THERE YET??

[waywardlad] 23/6/2008 10:53

none of my posts are any good


(i aint a respected poster)







YET!

[azuli] 23/6/2008 10:52

Good post by me on this thread.

[anotherguru] 23/6/2008 10:40

good post by wwl on the chat thread.

[waywardlad] 10/6/2008 18:36

wlu, if you dont like the header, you know what you can do!

[worlds lrgest undies] 10/6/2008 17:13

more of a scrutable type, I guess.

nice to see the fred back.


any chance about shortening the header a tad?

[waywardlad] 10/6/2008 16:06

please dont associate me with smelly breath vernit ;-)

[waywardlad] 10/6/2008 16:04

hahaha. keeping tabs on everyone!

[anotherguru] 10/6/2008 15:57

aye, i reckon he is a new vernit in the making. currently putting the guy down so he can strike and take over the 121 club mantle.























imho! (lol)

[anotherguru] 10/6/2008 14:56

ay, and it still has a cracking header!
even though wwl updates it so he thinks he can keep the best posts to himself.

[azuli] 10/6/2008 14:33

Retro fred muppetry. I like.

[baton] 20/5/2008 08:34

Thanks mrsloth. Updated now. :)

[mrsloth] 20/5/2008 07:44

Hi Baton,

I think you missed a bullet point in section 'Operational Highlights':

First order for TabWrap products

[rodrod1] 20/5/2008 02:32

Baton - thanks. thats a very helpful extraction for anyone doing their research; most appreciated as I had missed a couple of elements when reading the main document!

[baton] 20/5/2008 01:13

Extracts mentioning the TabWrap products from the 2007 preliminary results RNS dated 15 May 2008.

From the Operational Highlights bullet points section:

First order for TabWrap™ products


From the 'Operational Review' section:

A new branch of Dexo was also added in the key German market which benefited from relationships generated from the Group's OTC division, Melbrosin. It is fitting that this location, being the largest single EU pharmaceutical market, has been the one to act as the conduit for the Group's first analgesic TabWrap™ launch.

From the 'Development Review - Steve Martin - Chief Development Officer' section:

In a similar fashion to the sales and marketing divisions of the Company, the Group's development capability has grown significantly with over 45 projects at various stages of development. Products have been developed using the enabling technologies which have resulted in the generation of partnering and licensing revenues.

Not only has the market feedback from our product developments been strong but increasingly commercial partners are attracted by the relatively fast and secure methods employed by the Group in adding value to their own products and brands. Projects such as these are sensitive in nature and diverse in terms of stage development. However, not only is this area of the business producing valuable current and future revenue streams but also adding considerably to the asset value of the Group.

Meldex, therefore, not only has an expanding sales and marketing capability for a wide spectrum of products but is underpinned with a substantive low risk pipeline of a quality few can rival.

2007 was a pivotal year for the development programme both for products and the technologies. Speed of onset of action, as well as tablet-swallowing difficulties are key medical challenges. Meldex's development programmes, focusing on creating innovative patent-protected products, are aimed at overcoming these obstacles.

Of particular note are the developments associated with TabWrap™. Originally conceived as a mechanism to replace the gelatin coating of tablets, a technology only prevalent in the US OTC market, the system has expanded into several unique sub-technologies with Global appeal. Each of these sub-technologies address market need, whether that is for pharmaceutical partners or for the consumer themselves. TabWrap™ is one of the few dry tablet-coating systems and is unique in its ability to handle soft and fragile tablets on an individual basis.

Meldex is also positioning its TabWrap™ technology and its variants for use with small pharmaceutical companies. Using Meldex's formulation experience, it is able to offer partners enhanced patent protection around pharmaceutical developments, particularly around existing molecules. Revenue is generated during the formulation stage but the ultimate value is derived when the products are approved by regulatory authorities.

Meltums has proved to be a significant development for Meldex during 2007 with a vast potential for both products and partnering opportunities. A new enabling technology has been created which is currently being targeted to the confectionary, veterinary, nutritional, tobacco, dental and pharmaceutical markets. The response from all of these areas has been beyond expectations with the technology program being accelerated.


Highlighting some notable developments:-

FastWrap: - The system is being applied in indications where speed of onset of action is preferred. With the use of known pharmaceutical excipients, Meldex has shown that it can significantly improve the dissolution of certain products, particularly in the area of pain relief. A wide range of prescription and OTC medicines are in development or in launch programmes with partners. The DBP167 family of products have been clinically shown to be superior in terms of speed of onset of action compared to the market leading brand.

The technology is also being applied into the prescription market with a number of innovative products planned in a range of therapeutical areas including but not limited to pain and anti-inflammatory drugs. Some of these products are planned to enter the US market as patent-protected products through the Dexo US marketing division. In addition, the use of the technology, along with the anti-counterfeiting support system, is currently being promoted in the area of brand lifecycle management to the established pharmaceutical industry.

A range of products have been created specifically for the US market using the FastWrap principles which are based on either superiority or equivalence to existing brands on the market. This range of products is continuing to evolve in line with different partner expectations and will now be made available for Europe.

XLWrap: - This technology creates the ability to compress sustained release beadlets in to a tablet format. DBP355 is one development where this enabling system is being utilised with the ability to be a patent busting technology.

DuoWrap: - This is a combination of FastWrap and XLWrap designed to give optimal therapy options offering both speed and duration of onset of action. The technology is initially being targeted in the area of cough/cold and pain therapeutic segments, but work is currently being carried out into new therapeutical areas. The technology also has a number of applications within the lifecycle management area.

Meltums: - 2007 has seen the development of a novel non-compressive lozenge which is able to be adapted to include sustained release or taste masked beadlets. The concept of a melt-in-the-mouth product which is able to deliver a unit dose of sustained release medication is unique and has wide implications from OTC use through to palliative care, Parkinson's disease, Alzheimer's Disease and Attention Deficit and Hyperactivity Disorder (ADHD) from initial concept and drawings products are expected to be available within 2 years. Developments already include novel nicotine products for both the regulated and unregulated markets.

From the 'Post results events' section:

We are expecting 2008 to be exciting for other developments such as a nicotine and cigarette replacement which has received strong market interest. Both Meltums and Fastwrap will be core technology drivers throughout 2008 with the partner base extending outside of just the pharmaceutical sector. Data has been generated proving the Fastwrap concept with Ibuprofen showing superiority to existing competitor formulations.